Related Experiment Videos
Nitric oxide synthase inhibition reduces wakefulness
1Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, The Netherlands.
Neuropharmacology
|November 1, 1994
Summary
NG-monomethyl-L-arginine (L-NMMA) decreases wakefulness by inhibiting nitric oxide (NO) synthesis. Supplementing with L-arginine reversed this effect, indicating NO
Area of Science:
- Neuroscience
- Sleep Science
- Pharmacology
Background:
- Nitric oxide (NO) is a signaling molecule implicated in various physiological processes.
- The role of central NO in regulating sleep-wake patterns is not fully understood.
Purpose of the Study:
- To investigate the effects of inhibiting nitric oxide synthase (NOS) on the sleep-wake cycle in rats.
- To determine if L-arginine, a precursor of NO, can counteract the effects of NOS inhibition on sleep.
Main Methods:
- Rats were administered varying doses of NG-monomethyl-L-arginine (L-NMMA), a NOS inhibitor.
- Sleep-wake patterns were monitored following L-NMMA administration.
- The effect of L-NMMA was examined in conjunction with intracerebroventricular administration of L-arginine.
Main Results:
- L-NMMA administration dose-dependently reduced wakefulness.
- This reduction in wakefulness was accompanied by an increase in both slow-wave sleep and rapid eye movement sleep.
- The effects of L-NMMA were abolished by co-administration of L-arginine, suggesting a NO-dependent mechanism.
Conclusions:
- Central nitric oxide (NO) plays an excitatory role in regulating vigilance and wakefulness.
- Inhibition of NO synthesis leads to increased sleep.
- Factors influencing NO synthesis may impact wakefulness and contribute to sleep disturbances.